News

Dr. Lugogo explains how the ProAir Digihaler was used to accurately monitor SABA use in patients with asthma -many of whom were overusing their medication- which could allow clinicians to make appropriate changes to treatment.

The new study provides insights into the physiological factors for greater AtoOxy efficacy and can be referenced when identifying patients who are most suited for the therapy.

The media campaign to improve aspirin use included billboards, radio ads and print articles, in addition to a dedicated website.

A Massachusetts General Hospital investigator explains how the innovative DCD practice addresses both waitlist issues and transplant center's capabilities.

Elliot Israel, MD, and Juan Carlos Cardet, MD, MPH, join Lungcast to discuss their latest research into addressing Black and Latinx asthma outcome disparities.

Patients with a positive family history of OSA tended to be female with more severe OSA based on a higher AHI.

Obstructive sleep apnea has previously been associated with pulmonary hypertension in literature, with investigators citing a “complex and bidirectional relationship” between the 2 conditions.

Research has indicated that a fixed-dose combination of albuterol and budesonide could better reduce the risk of severe asthma exacerbation when compared to albuterol alone.

Patients treated twice-daily with an 18 mg dose of BI 1015550 experienced prevention of decreased lung function regardless of any background antifibrotic agents.

Dr. Chopra said an FDA-approved treatment for NAFLD could come in the next 6 months.

Dr. Gerald Smetana encourages PCPs to familiarize themselves with the outpatient drug options for managing COVID-19 because of the limited treatment window for administration.

The new drug-eluding stent can provide more flexible width size for patients with the potentially deadly disease.

Dr. Tara Vijayan talks about how primary care physicians can be best combat misinformation.

Expert psychiatrist Dr. Timothy Fong explains the complexity of using marijuana as treatment in a primary care setting and shares advice on how to address it with patients.

Alcohol use increased during the COVID-19 pandemic, leading to an increase in alcoholic hepatitis.

Promising 2-year data for the IL-17 targeting biologic were recently presented at AAD 2022.

High-risk individuals should be targeted when drug scarcity comes into play.

Patients who demonstrated high trough concentrations early on in treatment were more likely to achieve remission by weeks 14 or 52.

Among patients with early-onset AF, the presence of disease-associated rare variants in CM and arrhythmia genes was associated with a 1.5-fold higher risk of mortality over 10 years.

Subcutaneous administration of the gut-selective treatment was notably well-tolerated, safe, and cost-effective.

Aortic sclerosis, trace or mild aortic regurgitation, and mild mitral regurgitation each had significant associations with CV risk.

NAFLD is currently the most prevalent liver disease in the US.

Most research into the rare condition is focused on therapies and diagnostics, but investigators say it is important to better understand the disease’s impact on those around the patient.

Targeting a blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes than reserving treatment for severe hypertension.

The new analysis suggests the infections rarely leads to discontinuation in patients with atopic dermatitis.

Dr. Tara Vijayan speaks on improving COVID-19 treatment from “an equity standpoint, an ethical standpoint, and an evidence standpoint”.

There remains a need to develop more antivirals that can be easily scaled up for COVID-19.

These new data come as the FDA reviews the new drug application for deucravacitinib which, if approved, would make deucravacitinib the first allosteric tyrosine kinase 2 inhibitor approved for any disease.